Answer in brief
CVE-2026-123051 records a Low severity (CVSS 1.2) vulnerability in Hard-Coded OAuth Client Credentials in Farmasimplex REV.exe IZS Integration Module. The current sources do not mark it as known exploited. The current feed maps CIPCarbone srl/Farmasimplex REV.exe (generic). Check affected ranges and fixed versions before updating.
Analysis pending evidence review
HOL Guard separates source facts from reviewed analysis. See the methodology.
CVSS is 1.2. The current sources do not mark it as known exploited. Treat this as a source-backed prioritization signal, not a statement about your environment.
Analysis status
Analysis pending evidence review
Factual feed record only; HOL analysis is not approved for indexing. Read the methodology.
The current feed maps CIPCarbone srl/Farmasimplex REV.exe (generic). Check affected ranges and fixed versions before updating.
| Package | Affected range | Fixed version |
|---|---|---|
| CIPCarbone srl/Farmasimplex REV.exegeneric | >=0 <16.2.0 | 16.2.0 |
Published upstream
Nov 17, 2026
Evidence: source:cvelist:source_dates:source-dates:recordSource modified
Nov 17, 2026
Evidence: source:cvelist:source_dates:source-dates:recordFirst seen by HOL
Nov 17, 2026
The REV.exe module distributed with Farmasimplex contains embedded OAuth client credentials for integration with the IZS platform. An attacker with access to the executable could extract and reuse the credentials, potentially leading to unauthorized access to integration resources or manipulation of associated information, depending on the privileges granted and authentication controls in place.
Quoted source text, attributed separately from HOL analysis.